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DOSCATs: Double standards for 
protein quantification
Richard J. Bennett1, Deborah M. Simpson1, Stephen W. Holman1, Sheila Ryan2, 
Philip Brownridge1, Claire E. Eyers1, John Colyer3 & Robert J. Beynon1
The two most common techniques for absolute protein quantification are based on either mass 
spectrometry (MS) or on immunochemical techniques, such as western blotting (WB). Western blotting 
is most often used for protein identification or relative quantification, but can also be deployed for 
absolute quantification if appropriate calibration standards are used. MS based techniques offer 
superior data quality and reproducibility, but WB offers greater sensitivity and accessibility to most 
researchers. It would be advantageous to apply both techniques for orthogonal quantification, but 
workflows rarely overlap. We describe DOSCATs (DOuble Standard conCATamers), novel calibration 
standards based on QconCAT technology, to unite these platforms. DOSCATs combine a series of 
epitope sequences concatenated with tryptic peptides in a single artificial protein to create internal 
tryptic peptide standards for MS as well as an intact protein bearing multiple linear epitopes. A DOSCAT 
protein was designed and constructed to quantify five proteins of the NF-κB pathway. For three 
target proteins, protein fold change and absolute copy per cell values measured by MS and WB were 
in excellent agreement. This demonstrates that DOSCATs can be used as multiplexed, dual purpose 
standards, readily deployed in a single workflow, supporting seamless quantitative transition from MS 
to WB.
Accurate quantification of proteins is of critical importance in cell biology, proteomics, clinical biomarker dis-
covery and systems biology. Two very different approaches to quantification are routinely adopted; those based 
on mass spectrometry (MS) and those based on (semi) quantitative western blotting (sqWB). The two methods 
differ, both in the technical demands and in the complexity of the associated equipment, as well as the confidence 
in the quantitative data generated.
Mass spectrometric methods are considered to be the gold standard for targeted protein quantification1–3. 
However, capital investment and the expertise required in setting up and executing an MS assay means that it 
is less widely used than sqWB. For relative MS quantification, there is increasing application of label-free quan-
tification based on the intrinsic signal intensity of individual peptides (derived from a digested protein) or of 
label-mediated quantification in which stable isotope labels are used to discriminate between two or more con-
ditions, discriminated by the mass shift either at the level of the peptide ion or at the level of fragment ions 
generated within the mass spectrometer. Label based quantification methods are commonly used in conjunction 
with a targeted MS approach known as selected reaction monitoring (SRM). SRM utilises triple quadrupole mass 
spectrometers to perform two levels of mass selection, at the level of both precursor and product ion, giving much 
improved selectivity and sensitivity over global, ‘discovery’ proteomic approaches. Semi-quantitative western 
blotting is, by contrast, readily delivered with a small investment in equipment, and in most laboratories, requires 
extended sequences of manual processing steps (although there are instrumentation developments that automate 
the method). Although considered a semi-quantitative technique for relative quantification of signal intensity, 
sqWB is commonly used to draw quantitative conclusions despite the lack of calibration standards, rigorous (and 
standardised) methodology, and consistent data analysis4,5. However, direct comparison of sqWB results between 
groups is problematic as the data (effectively, the intensity of an antibody–reactive band that is generated by differ-
ent chemistries and measured using different imaging devices) are dimensionless and highly variable (inter-assay) 
despite high levels of care and skill by the researcher. This limitation is likely to have contributed to the lack 
of reproducibility in pre-clinical data, which has a high cost in terms of wasted effort and delayed progress6,7. 
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Many papers that report sqWB data do not include exhaustive data that defines the specificity of the 
antibody-antigen interaction, linearity of response or evidence that the immunoreactive band is the target anti-
gen. Indeed, it is common practice in publication of sqWB results to crop western blot images to the region of 
interest, thus obscuring other regions of cross-reactivity. In sqWB, quantification is usually relative, where one 
condition is compared with a second, ideally run on the same gel and developed as a single blot.
For absolute quantification, calibration standards based on stable isotope labelled proteins or peptides (for 
MS) or epitope bearing proteins (for WB) are required. Isotope standards for MS, based on relatively short tryptic 
peptides, are not suitable for western blot quantification, such that MS-based and WB workflows rarely over-
lap. Ideally, there would be readily deployable technologies to converge techniques, raising standards in quan-
titative output. There is a continuing need for appropriate calibration standards in the western blot workflow, 
thereby creating genuinely quantitative western blotting (QWB). Further, it would be ideal if calibration standards 
were capable of deployment across both MS and QWB workflows. This crossover would allow for validation 
of the orthogonal techniques and comparison of data between the two most common quantitative techniques. 
Moreover, QWB could be used to improve characterisation of research antibodies (sensitivity, dynamic range, 
limit of detection, consistency of batches, specificity), which is currently problematic8,9 and a major factor in the 
irreproducibility of pre-clinical science5. Indeed, the use of orthogonal techniques such as MS to validate antibody 
specificity has been proposed by an international working group of scientists10.
It is easy to understand why western blotting is the preferred method (Pubmed searches reveal approximately 
5,000 citations using the terms ‘SRM or MRM’, compared to over 250,000 using the terms ‘western blot’ or ‘west-
ern blotting’), as it is readily deployable in most laboratories and does not require access to either the special-
ist instrumentation or the cognate expertise that is needed to develop an MS-based method. However, there is 
considerable scope for studies that compare and explore the comparative performance of the two approaches. 
Indeed, it is a common experience with MS-based proteomics studies that reviewers request ‘validation’, implic-
itly meaning western blotting, without any evidence for the ability of both methods to deliver comparable data 
sets1. In pursuit of reliable approaches to quantitative western blotting, there is merit in comparison of such 
approaches with an orthogonal method, such as those based on mass spectrometry. Further, QWB methods give 
added information about electrophoretic mobility (crudely indicative of protein mass), information that is absent 
from ‘bottom-up’ proteomics.
We have previously designed and employed artificial proteins to solve problems in MS-based analyses, includ-
ing QconCATs11 for absolute quantification and QCAL12, QCAL-IM13 and RePLiCal14 as universal standards for 
MS-based techniques. In particular, we developed QconCAT proteins to facilitate multiplexed protein quanti-
fication by MS11,15. QconCATs are artificial genes encoding proteins that are concatenations of (usually tryptic) 
peptides from multiple proteins (typically up to 25) that act as ‘quantotypic’ standards when the calibrator protein 
is expressed in bacteria and labelled with stable isotope amino acids16. After co-digestion of the analyte (in a bio-
logical sample) and the QconCAT, the resultant pairs of unlabelled (analyte) and labelled (standard) peptides can 
be analysed by mass spectrometry, permitting accurate quantification of the analyte protein abundance.
Here, we extend QconCAT principles to design DOSCATs ‘DOuble Standard conCATamers’, dual-purpose 
calibration standards for MS-based quantification and/or QWB, also designed de novo and expressed heterolo-
gously in Escherichia coli. DOSCATs concatenate epitope sequences from one or more proteins recognised by 
multiple antibodies. They also embed quantotypic peptides (Q-peptides) for MS quantification of the same pro-
teins (Fig. 1) and thus act as a single multiplexed standard that can be used for MS-based or QWB quantification. 
For added flexibility, the epitopes can be interspersed with restricted specificity endoproteolytic sequences, which 
permit generation of quantification standards of optimal mobility in sized-based or charge-based separation plat-
forms. The DOSCAT design includes a His-tag for purification and glufibrinopeptide B (Glu-Fib) sequence for 
quantification of the standard17 and contains at least two Q-peptides for each target protein, chosen according 
to well-defined criteria16,18. It is axiomatic that the epitopes can only be used if they are relatively short peptide 
sequences, either used as an immunogen or identified as the linear sequence that is recognised by a monoclonal 
antibody. The aim of this work is to demonstrate that DOSCATs can be used as a calibration standard across both 
SRM and QWB workflows to deliver equivalent quantitative results.
Results and Discussion
DOSCAT design, expression and purification. For DOSCATs, epitopes for a small panel of antibodies 
are inserted into the protein in addition to Q-peptides so that the standard can be deployed across both MS and 
QWB workflows. A minimum of two Q-peptides were chosen for each target protein based on a well-defined pro-
cess16,18. The data repositories PeptideAtlas (http://www.peptideatlas.org/) and Global Proteome Machine (http://
www.thegpm.org/) were initially consulted and peptides identified. Where peptides could not be identified using 
this approach (for Iκ Bα and RelB), peptides were selected on the basis of a computational prediction of their 
quantotypic propensity based on physio-chemical properties and predicted observability (PeptideSieve score 
(http://tools.proteomecenter.org/wiki/index.php?title= Software:PeptideSieve)). For all selected Q-peptides, 
uniqueness in the proteome was confirmed by BLAST searches. Each peptide was supplemented with natural 
flanking sequences of 3 amino acids in length as a strategy to improve quantitative accuracy by equalising diges-
tion efficiency between standard and analyte19 (Supplementary Table 1). For p65 and Iκ Bβ , selected Q-peptides 
were adjacent in the protein sequence so flanking regions were not possible nor required. Epitopes included 
in the DOSCAT sequence were chosen based on the immunogen sequence supplied by the manufacturer 
(Supplementary Table 2). Where the precise immunogen sequence was disclosed by the manufacturer, this was 
used in the DOSCAT - this was the case for Iκ Bβ and Iκ Bε . For some antibodies, only the specific residue around 
which the epitope was centred was disclosed and in these instances, up to 25 amino acids flanking each side of the 
central residue in the protein sequence were used to ensure inclusion of the epitope in the DOSCAT sequence. 
This was required for the epitopes for p65, RelB and Iκ Bα .
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To introduce the possibility of manipulation of mobility in QWB, several restricted specificity endopeptidase 
sites were included in the DOSCAT design. These sites were selected based on the primary sequence specificity 
and the commercial availability of the protease. Four endopeptidases were used (Supplementary Table 3) and for 
each, the target sequence was unique to a single site in the DOSCAT and was absent from any of the target pro-
teins. Cleavage sites were inserted into the sequence between epitopes so that proteolysis would generate two frag-
ments that could be detected by different antibodies and which would have a different electrophoretic mobility 
to the parent DOSCAT, permitting a mobility shift to prevent overlap between standard and analyte. Additional 
amino acids were added at the N-terminus to provide an initiator methionine and a sacrificial N-terminal region 
as well as glufibrinopeptide B peptide (EGVNDNEEGFFSAR) for MS-based quantification of the standard3. A 
hexahistidine tag was added at the C-terminus to allow affinity purification. Once the protein sequence was 
designed (Fig. 2a) and the codon optimised gene was synthesised, the DOSCAT was expressed successfully in 
E.coli in minimal medium (Fig. 2b), accumulating in inclusion bodies, and after solubilisation in a chaotrope was 
readily purified by Ni-NTA affinity chromatography (Fig. 2c). The protein sequence and optimised gene sequence 
for the DOSCAT are included in Supplementary Information.
Validation and performance in QWB and SRM. After purification, the DOSCAT was homogenous on 
SDS-PAGE and western blotting using an anti His-tag antibody (Fig. 2d) confirmed that there was no proteol-
ysis of the protein during expression or purification. Moreover, western blotting using p65 and RelB antibodies 
(the epitopes to which are at the N-terminal end), demonstrated there was no degradation or fraying at the 
N-terminus of the protein (Supplementary Fig. 1). After expression and purification, the DOSCAT was subject 
to tryptic digestion and the peptides were analysed by LC-MS/MS on a Synapt G2. This confirmed that the pro-
tein sequence was correct with 83% sequence coverage and 11 of the 13 nominated Q-peptides being identified 
by LC-MS/MS (Fig. 2e). The peptide DAGADLDKPEPTCGR was not identified due to a miscleavage event at 
the N terminus. Only the miscleaved peptide, containing the preceding residues DDDDK, the cleavage site for 
enteropeptidase, was detected. It is known that acidic residues around the scissile bond can inhibit proteolysis20,21; 
therefore, it is likely that the sequence context around the peptide was the reason for the miscleavage. Care should 
be taken in placing Q-peptides next to such residue sequences when designing future iterations of DOSCATs and 
this observation casts doubt on the utility of enteropeptidase as a restricted specificity proteinase in this appli-
cation. Additionally, the peptide SPLHLAVEAQAADVLELLLR was not detected either by database searching 
or in the raw data. This was further investigated by running the same DOSCAT digest on a QExactive Orbitrap 
instrument. The peptide was detected by database searching and in the raw data, but with a signal intensity ~0.1% 
of the base peak intensity. This lack of detectability on two separate instrument platforms confirm poor ionisation 
efficiency or fragmentation of the peptide after ionisation. When the DOSCAT was expressed in minimal media 
containing [13C6]Lys and [13C6]Arg as the sole source of these amino acids, complete labelling (> 99%) of the pro-
tein was confirmed by the examination of MS1 data and extracted ion chromatograms (Fig. 2f).
Figure 1. Principle of DOSCAT design. Peptides for MS-based quantification and antibody epitopes are 
selected for each target protein and sequences concatenated into a single artificial protein (DOSCAT). Tag 
sequences for quantification and purification of DOSCAT are inserted at each terminus. Restricted specificity 
endopeptidase sites are interspersed throughout the sequence so as to permit generation of quantification 
standards of optimal mobility during sized-based separation analysis.
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Figure 2. Design of a DOSCAT for quantification of members of the NFκB pathway. (a) Protein map of 
the NF-κ B DOSCAT. Green boxes represent quantotypic peptides, red boxes define the extent of antibody 
binding epitopes and purple boxes the glu-fibrinopeptide B calibration peptide at the N-terminus and 
the His6 purification tag at the C-terminus. Arrows indicate the location of cleavage sites for each of the 
specific proteases (TVMV, tobacco vein mottling virus protease; RV3C, human rhinovirus 3 C protease; EP, 
enteropeptidase; TEV, tobacco etch virus protease. SDS-PAGE analysis of (b) E. coli culture time points 2–6 hrs 
after inoculation, with expression induced by IPTG after 3 hrs and (c) pre-purification starting material (SM) 
alongside elution fractions 1–7 from His-Trap column using an elution gradient 0–100% elution buffer over 
20 min. (d) Western blot analysis of 50 ng purified DOSCAT using an anti His-tag antibody. (e) DOSCAT 
peptide map highlighting Q-peptides identified (green) and not identified (white with cross) by MS/MS, 
alongside the MS1 total ion chromatogram signifying the elution profile of each Q-peptide. (f) Mass spectra and 
SRM chromatogram for a representative Q-peptide demonstrating high stable isotope labelling efficiency.
www.nature.com/scientificreports/
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For a DOSCAT to be used for the accurate quantification of target proteins, complete and equivalent digestion 
of standard and analyte is crucial. Although it is possible that peptides may be released more quickly from either 
standard or analyte, the rate of digestion in both should reach a plateau before analysis22. To ascertain whether 
there was complete release of Q-peptides from the DOSCAT, the standard was spiked into SK-NA-S cell lysate 
and the digestion mixture was sampled at regular intervals. Rates of excision of standard and analyte peptides 
varied (for exemplars, see Fig. 3), but in all instances the proteolysis attained a stable plateau before the end of 
the overnight incubation period (Supplementary Fig. 2). Differences in the rate of digestion between standard 
and analyte are thus rendered moot by the simple expedient of establishing conditions that allow the reactions to 
proceed to completion.
To define the transition of the SRM assays, a tryptic digest of the DOSCAT was analysed by LC-MS/MS using 
a Q-TOF mass spectrometer. For each peptide, MS/MS fragmentation data were used to identify optimal transi-
tions for each peptide (Supplementary Fig. 3). These transitions were then used to build a scheduled SRM profile 
and a programme of timed transitions resulted in cleanly isolated peaks specific for all but two of the Q-peptides 
(Fig. 4). To determine performance in a complex matrix, DOSCAT was spiked in SK-NA-S lysate at concen-
trations over a 1000-fold range and analysed by SRM. The signal linearity varied for each peptide, with some 
peptides exhibiting a linear relationship of the entire measured range. Moreover, the limits of detection (LOD) 
(based on a signal to noise ratio of 3) also differed for each peptide (Supplementary Fig. 4) with an average LOD 
of 100 amol. Based on the number of cell equivalents loaded onto the column, this corresponds to about 10,000 
copies per cell.
To validate the DOSCAT for western blotting, dilution series of the standard protein were loaded onto the cap-
illary western blotting system and were detected independently by each of the five commercial antibodies (Fig. 5). 
Sensitivities varied for different antibodies, ranging from 5 amol to 1.5 fmol in each lane, defined as the lower limit 
of quantification. Based on the number of cell equivalents that were loaded into the capillaries, this equates to 
about 1000 copies per cell for the lowest limit of detection. Iκ Bε could not be quantified using this methodology 
as the antibody did not detect the epitope in DOSCAT. However, when used against SK-NA-S cell lysate in both 
capillary and classic western blotting, the antibody detected a band at ~90 kDa (data not shown), very different 
from the expected molecular weight (53 kDa). We conclude that the antibody was unreliable and it was not used 
in further experiments.
Although this DOSCAT met many of the criteria of a dual-purpose standard, the critical test of such a stand-
ard is in the quantification of endogenous proteins. Specifically, would both QWB and MS assays yield accept-
able quantification, and secondarily, would the presence of a complex background such as a cell homogenate 
impair the ability to use the standard? Further, the migration of the DOSCAT in the capillary QWB system had 
the potential to lead to interference with the signal for the endogenous analyte. To explore a realistic scenario 
for deployment of the artificial dual standard, DOSCAT was spiked into protein extracts of unstimulated and 
TNFα -stimulated SK-N-AS cells. The same cell lysates, spiked with the DOSCAT standard, were used for MS 
or QWB quantification, the difference being that for QWB, the spiked lysates were analysed without further 
treatment, whereas for MS quantification, the mixture was reduced, alkylated and proteolysed with trypsin. The 
DOSCAT was accurately quantified against an unlabelled Glu-Fib standard17,23 before subsequent SRM-MS and 
QWB analysis.
QWB was performed on the same samples in parallel with SRM-MS. The DOSCAT was serially diluted in 
SK-N-AS cell lysates to create an internal calibration series for each lysate. DOSCAT/lysate mixtures were ana-
lysed by automated western blotting system with antibodies that were specific and had been validated for each 
of the target proteins. The DOSCAT was designed to migrate at an apparent molecular weight (Mr) that differed 
Figure 3. Time course to complete digestion of DOSCAT and sample. Stable isotope labelled DOSCAT 
and SK-N-AS lysate was co-digested with samples taken at a series of time points and analysed by SRM-MS. 
The ratio of heavy (DOSCAT) and light (endogenous) peptides was calculated at each time point. Displayed 
are exemplar plots for the three types of observed digestion behaviour: peptide release in standard and analyte 
digestion being equal and rapid (STANDARD = ANALYTE), faster in analyte (ANALYTE > STANDARD), or 
faster in standard (STANDARD > ANALYTE). Red lines indicate general trend of H:L ratio over time.
www.nature.com/scientificreports/
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from endogenous target proteins, allowing separation of signal between the exogenous DOSCAT standard and 
endogenous analytes (Fig. 5). In practice, we observed some baseline interference at very high loadings of stand-
ards when the DOSCAT and analyte were similar in mobility, leading to less accurate quantification of peak area 
(Supplementary Fig. 5). This was readily resolved by restricting the standard data points to exclude the highest 
internal DOSCAT concentrations (Supplementary Fig. 6). This adjustment was applied for all target proteins, 
regardless of similarity in mobility between analyte and standard. Moreover, analyte levels were always within the 
linear calibration region of the standard curve. The DOSCAT signals were used to construct calibration curves 
that were linear in all cases (r2 > 0.98, exemplar in Fig. 5, all data in Supplementary Fig. 7).
For SRM-MS, the extracted ion chromatograms for unlabelled analyte and the labelled Q-peptide (released 
from DOSCAT) were used to calculate the amount of analyte present, as copy number per cell (cpc) values 
(using the calculation described in Materials and Methods). Protein level quantification values were calculated 
by averaging peptide values across technical replicates and in turn, taking the mean of the values obtained for 
different peptides. More than one peptide per protein was detected for p65 and RelB; for p65 the peptide cpc 
values were in good agreement but for RelB, SGPASGPSVPTGR gave lower cpc values than the other peptides 
(Supplementary Fig. 8). This may be due to the proximity of the endogenous peptide to the N-terminus or the 
presence of a previously unknown post translational modification on the peptide, and such the peptide was not 
included in calculating the final cpc value. Despite nominating peptides based on experimental evidence, neither 
Iκ Bβ , Iκ Bε nor the the Iκ Bα peptide GSEPWK could be quantified by SRM-MS due to a combination of miscleav-
age potential in the standard, poorly performing peptides and the intrinsic low abundance of the target proteins16.
Two measures were used to compare the performance of the orthogonal analytical approaches. First, each 
method yielded absolute quantification values in copies per cell. Secondly, the changes in protein abundance after 
stimulation by TNFα could be compared. The utility of DOSCAT was demonstrated by quantification of five 
target proteins in the NF-κ B pathway using both quantitative platforms. Exposure of cells to the cytokine TNFα 
significantly increases the levels of endogenous RelB and elicits degradation of the inhibitor proteins of NF-κ B, 
Iκ Bs24. DOSCAT standardised quantification by SRM-MS or QWB were consonant with this expectation, giving 
confidence to the method. Although only a relatively small number of proteins were quantified in this study, 
agreement in copy numbers between the two techniques were improved compared to other studies that have com-
pared MS and WB quantification3,25,26. In terms of both copies per cell and relative fold change, quantitative values 
generated by QWB and SRM-MS were in agreement for the 3 out of 5 proteins where comparison was possible 
(Fig. 6a,b). Moreover, both techniques demonstrated high precision with a mean % CV across both techniques 
Figure 4. Summary of scheduled SRM-MS assays for Q-peptides contained in DOSCAT. Extracted ion 
chromatogram from SRM-MS analysis of 1 fmol digested DOSCAT loaded onto the column, detailing the peak 
intensity and retention time for all Q-peptides for which scheduled SRM-MS assays were built. Inset: DOSCAT 
peptide map illustrates all Q-peptides for which SRM-MS assays were designed (bright green boxes) out of all 
observed peptides (pale green boxes) alongside product ions monitored for each peptide. Two Q-peptides were 
not detectable by SRM-MS (white box with cross). Inset table contains a detailed list of transitions for each 
peptide.
www.nature.com/scientificreports/
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of 14% (biological replicates, n = 3). This is a clear demonstration that careful design of standards, coupled with 
appropriate technology and experimental design can converge these orthogonal methodologies.
Accurate protein quantification by orthogonal techniques is desirable to increase accuracy and robustness 
of quantitative data, especially important in systems analysis of specific pathways or biomarker validation. 
Quantification by two methodologies in parallel in a single experiment is difficult, though, due to differences 
in calibration standards. To address this problem we have proposed DOSCATs as a single calibration standard 
to support quantification by both QWB and SRM-MS assays across a single workflow. In some instances, QWB 
allowed quantification whereas SRM-MS did not, due to lack of peptide detection at low protein abundance and 
poor peptide ionisation. This further emphasises the value of using orthogonal techniques to quantify proteins 
across a wide dynamic range, or small proteins where options for Q-peptides are restricted. In our hands both 
quantitative platforms demonstrated an equivalently high level of precision using DOSCAT, which was within the 
range typically reported for SRM and QWB (using Simple Western technology) assays3,27,28. Using ‘classic’ western 
blotting, it would be anticipated that reproducibility would be lower due to the greater number of manual han-
dling steps. With rigorous experimental design and well validated antibodies5,29, there is no reason why similarly 
equivalent quantitative data could be obtained using DOSCAT as a calibration standard.
Based on well-established QconCAT technology for which much of the route to deployment is well charac-
terised23,30 (~900 citations citing QconCATs are recorded in Google Scholar as of December 2016), the DOSCAT 
workflow is simple to implement (a generic workflow is presented in Fig. 7). Since the initial publication in 200511, 
over 200 QconCATs have been utilised in a range of quantitative studies. QconCATs differ to natural proteins in 
amino acid composition17 and almost always accumulate in inclusion bodies. Expression in inclusion bodies can 
provide a useful pre-purification step but can also create problems of insolubility in long-term storage post puri-
fication – the use of MS-compatible detergents such as RapiGest SF and a low concentration of a reducing agent 
can minimise such problems17. The NF-κ B DOSCAT expression is resonant with these previous observations, 
and we would expect future DOSCATs to follow this trend. In terms of design, selection criteria for Q-peptides 
are well documented16,18 and can equally be applied to DOSCATs. Of course, the availability of antibodies that are 
cross-reactive to known linear epitopes is a limiting factor when constructing a DOSCAT. However, a search for 
the term ‘synthetic peptide’ in the CiteAb (https://www.citeab.com/) database revealed over half a million anti-
bodies raised to linear synthetic peptides. Thus, in an environment that was permissive to collaboration with anti-
body manufacturers, or where custom antibodies are made in-house, these peptide sequences could be included 
in DOSCATs. We encourage antibody manufacturers and suppliers to release the peptide sequences used for 
antibody generation as a contribution to reproducible research but also, to ease the construction of standards such 
as DOSCATs. If restricted proteolytic sites are built into the DOSCAT sequence, there is also an element of adapt-
ability in the workflow so that fragments of a predictable electrophoretic mobility are produced upon incubation 
with specific proteases. This not only allows for additional flexibility if the DOSCAT standard migrates at a similar 
mobility to endogenous proteins but the ability to create standards containing epitopes separable by limited pro-
teolysis can assist in multiplexed protein detection in a single lane or capillary of a western blot.
DOSCATs offer a new calibration tool for protein quantification by both SRM-MS and QWB and unite two 
disparate workflows by a single calibration standard yielding equivalent quantification. Western blotting is one of 
Figure 5. Quantitative western blots. Representative Simple Western data for 0.4 μ g/μ l SK-NA-S cell 
lysate ± TNFα stimulation spiked with a dilution series of DOSCAT and probed with antibodies for each target 
protein, shown in electropherogram view (top) and gel view (middle). Bottom: Calibration curves generated by 
DOSCAT for each protein. Data presented as mean ± standard error (n = 6).
www.nature.com/scientificreports/
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the most widely used research techniques practised by the majority of cell biologists, despite previous limitations 
in delivering quantitative data. The DOSCAT approach has the potential to enhance the rigour of QWB that is 
more readily applied after MS validation, to generate reliable quantitative information particularly relevant for 
systems biology studies and contribute to the desired increase in reproducibility of biological research.
Materials and Methods
Materials. Antibodies used in this study are detailed in Supplementary Table 2.
DOSCAT design. DOSCATs are based on QconCAT design principles, in which quantotypic peptides are 
concatenated in silico to create an artificial protein11. For DOSCATs, epitopes for multiple antibodies and specific 
protease cleavage sites are inserted into the protein as well as quantotypic peptides. A minimum of two quan-
totypic peptides were chosen for each target protein for SRM. The data repositories PeptideAtlas and Global 
Proteome Machine were initially consulted and suitable peptides were identified based on well-defined crite-
ria16,18. Natural flanking sequences consisting of 3 amino acids from the endogenous protein were added to each 
end of every peptide31. This strategy has been shown to improve quantitative accuracy by equalising digestion 
efficiency between standard and analyte. Where peptides could not be identified (notably, Iκ Bα and RelB) other 
quantification peptides for DOSCAT were selected based on their PeptideSieve score and predicted observability.
Epitopes included in the DOSCAT sequence were chosen based on the immunogen sequence supplied by the 
manufacturer (Supplementary Table 2). If the full immunogen sequence was disclosed by the manufacturer, this 
was used in the DOSCAT, as was the case for Iκ Bβ and Iκ Bε . For some antibodies only the residue around which 
the epitope was centred was disclosed. In these cases up to 25 amino acids either side of the central residue in 
the protein sequence were used in the DOSCAT sequence, specifically for p65, RelB and Iκ Bα . Proteases were 
selected based on the specificity of their cleavage motif and commercial availability. Cleavage sites were inserted 
into the sequence between epitopes so that proteolysis would result in two fragments that could be detected by 
different antibodies. Additional amino acids were inserted at the N-terminus to provide an initiator methio-
nine as well as a glufibrinopeptide B (EGVNDNEEGFFSAR) for standard quantification. A hexahistidine tag 
was added at the C-terminus to enable purification. Protein and DNA sequences as FASTA files are included in 
Supplementary Information.
Expression and purification of stable isotope labelled DOSCAT. The gene for the DOSCAT protein 
was optimised for expression in Escherichia coli, synthesised and ligated into a pET21a plasmid vector (Eurofins 
Genomics, Ebersberg, Germany). The plasmid was transformed into competent BL21 DE3 E.coli cells, which 
were cultured in minimal media containing 13C6 labelled arginine and lysine as previously described23. DOSCAT 
expression was induced by Isopropyl β -D-1-thiogalactopyranoside (1 mM) when the culture OD at 600 nm 
reached 0.6. E.coli cells were separated from culture media by centrifuging at 3500 × g, 15 min, 4°C. Cell pellets 
from 50 mL culture were resuspended in 2.5 mL sonication buffer (50 mM NaPO4, 25 U/mL Benzonase Nuclease 
(Novagen), 1× Complete EDTA-free protease inhibitor tablet (Roche), pH 8.0). Cells were sonicated on ice using 
10 sec pulses at 30% amplitude delivered from a 3 mm probe of a Sonics Vibra Cell™ (Jencons Scientific Ltd, UK) 
until 130 joules was reached.
The E.coli lysate was centrifuged at 6000 g, 8 min, 4°C to separate insoluble and soluble fractions. DOSCAT 
was present in the insoluble inclusion body pellets, which were solubilised by incubating for 30 min in 4 mL 
20 mM NaPO4, 0.5 M NaCl, 10 mM imidazole, 6 M guanidine hydrochloride, pH 7.4. Inclusion body samples 
were filtered using a 1.20 μ m syringe filter (Milliex GP, Merck Millipore, UK) before purification of the His-tagged 
DOSCAT on a 1 mL His-trap HP column (equilibrated in the solubilisation buffer, above) using the ÅKTA start 
system (GE Healthcare). Bound proteins were eluted by applying a linear gradient of 0–100% elution buffer 
Figure 6. Target protein quantification. (a) Comparison of absolute quantification values for each target 
protein as obtained by SRM-MS and QWB. Quantification of Iκ Bβ using SRM was not possible. Data presented 
as mean ± standard error (n = 3). (b) Relative fold change of proteins in TNFα treated and untreated SK-NA-S 
cells as measured by quantitative western blotting (QWB) and selected reaction monitoring (SRM-MS). Data 
are presented as mean ± standard error (n = 3).
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(20 mM NaPO4, 0.5 M NaCl, 0.5 M imidazole, 6 M guanidine hydrochloride, pH 7.4) over 20 min at a flow rate 
of 1 mL/min. Eluted fractions containing DOSCAT were pooled and dialysed against 50 mM ammonium bicar-
bonate (NH4HCO3), 1 mM DTT, pH 8.5. RapiGest SF (Waters, UK) was added to the storage buffer at a final 
concentration of 0.1% (w/v) in order to reduce DOSCAT adsorption to plastic surfaces. DOSCAT solution was 
aliquoted and stored in low bind tubes (Corning, USA) at − 20°C.
Harvesting, counting and sonication of cell lysates. SK-N-AS cells between passages 7–14 were 
grown to 80% confluency in 75 cm2 flasks in Minimum Essential Media (37°C, 5% CO2/humidity). In each set of 
experiments a set of three cultures were stimulated with TNFα (10 ng/mL) for a period of 24 hrs. At the same time 
media was replaced on the unstimulated cells without added TNFα . To harvest cells, media was aspirated and 
adherent cells were washed three times with sterile PBS (5 mL). Cell dissociation buffer (1 mL) was added and the 
cells placed in the incubator at 37°C for 5 min. PBS (4 mL) was added to each flask and the contents of each flask 
transferred to individual 15 mL Falcon tubes. Cells were dispersed by repeated uptake and aspiration from a 5 mL 
pipette and 50 μ L of cell suspension was removed and added to an equal volume of 0.4% (w/v) trypan blue in PBS. 
Immediately after mixing, dye suspension (10 μ L) of cells was pipetted into each of the two chambers of a count-
ing slide and cell numbers counted in a TC10 cell counter (Bio-RAD, Hemel Hempstead, UK). The counter gave a 
direct reading of the total cells/mL and the viable cells/mL of suspension. Cells were harvested by centrifugation 
at 160 g (Eppendorf, Cambridge, UK), supernatant removed and cell pellets stored at − 20°C.
Figure 7. Overall DOSCAT workflow. The deployment of DOSCAT quantification can be resolved into three 
phases; design, expression and assay development. This workflow summarises the major steps.
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Cell pellets were re-suspended in 25 mM ammonium bicarbonate (not pH adjusted) at 100 μ L/1 × 106 cells and 
sonicated on ice using three 10 sec pulses at 30% amplitude delivered from a 3 mm probe of a Sonics Vibra Cell™ . 
Benzonase nuclease (2.5 U/100 μ L cell lysate) was added and the cell lysate was held on ice and not fractionated 
further.
Protein determination. Protein was assayed using a modified Bradford assay. Cell lysate and DOSCAT 
were diluted 1:50 and 1:100 in Milli-Q (18 Ω ) water and 100 μ L of each sample added to a microtitre plate in 
duplicate followed by the addition of 200 μ L protein assay reagent (Thermo Fisher Scientific, Cramlington, UK). 
The plate was read at 600 nm on a microplate reader (Multiscan) using Ascent software (Thermo Fisher Scientific) 
and protein concentrations interpolated from a BSA standard curve.
DOSCAT and SK-N-AS cell lysate sample preparation. A known concentration of DOSCAT was 
spiked into SK-N-AS lysate and RapiGest SF added at a final concentration of 0.1% (w/v) to create a starting 
master mix, which was subsequently used for both SRM-MS and QWB workflows. A sample of the master mix 
was digested, accurate DOSCAT concentration determined using glufibrinopeptide B (Severn Biotech, > 98% 
purity), and targeted protein quantification performed by SRM. The same master mix was then used for quanti-
tative western blotting.
In solution co-digestion. A volume of master mix equivalent to 70 μ g total protein in cell lysate was pro-
cessed through the tryptic digest protocol. Alongside the cell lysate/DOSCAT co-digest, a cell lysate only digest 
was performed in parallel for each biological replicate. The samples were made up to 160 μ L by the addition of 
25 mM ammonium bicarbonate and proteins were denatured by the addition of Rapigest (0.1% w/v) and heating 
at 80°C for 10 min. The sample was then reduced (addition of 10 μ L 60 mM DTT and heating at 60°C for 10 min) 
and alkylated (addition of 180 mM iodoacetamide and incubation at RT for 30 min in the dark). In digests con-
taining DOSCAT, 4.5 μ L 500 fmol/μ L glufibrinopeptide B was added. Mass spectrometry grade trypsin (Promega, 
USA) was reconstituted in 50 mM acetic acid to 0.2 μ g/μ L and 10 μ L added to digests followed by incubation 
at 37°C for 4.5 hrs. At this stage an additional 2 μ g trypsin was added and the sample incubated at 37°C over-
night. The digestion was ended and RapiGest SF removed by acidification (1.5 μ L trifluoroacetic acid followed 
by incubation at 37°C for 45 min). Digests were made up to 225 μ L by the addition of acetonitrile:water (2:1) and 
precipitate (resultant from the breakdown of RapiGest SF) removed by centrifugation (13,000 g, 30 min, 4°C). 
Supernatant was removed from the precipitate pellet and carried forward for use as sample.
Quantification of labelled DOSCAT using glufibrinopeptide B peptide standard. Samples were 
analysed using nanoAcquity UPLC™ system (Waters) coupled to a Xevo™ TQS triple quadrupole mass spec-
trometer (Waters) in SRM mode with Q1 and Q3 operating at unit mass resolution. Digested sample (1 μ L) was 
loaded onto a trapping column (C18, 180 μ m × 20 mm, Waters) using partial loop injection for 3 min at a flow 
rate of 5 μ L/min with 0.1% (v/v) formic acid. The sample was resolved on the analytical column (nanoACQUITY 
UPLC HSS T3, C18, 75 μ m × 150 mm × 1.8 μ m column, Waters) using a gradient of 97% A (0.1% (v/v) formic 
acid) 3% B (99.9% (v/v) acetonitrile, 0.1% (v/v) formic acid) to 60% A 40% B over 30 min at a flow rate of 300 nL/
min followed by washing with buffer B and re-equilibration. SRM analysis was performed using an electrospray 
voltage of 3000 V and a source temperature of 80°C. Glufibrinopeptide B was detected by measuring three transi-
tions of both isotopic variants over the entire course of the chromatographic run. Quantification was performed 
by integrating extracted ion chromatograms in heavy and light channels and comparing the two.
Quantification of peptides by SRM and data analysis. Quantification was performed on a Xevo™ 
TQS triple quadrupole mass spectrometer coupled to a nanoAcquity UPLC™ system (Waters) (using the param-
eters described above). Analysis was performed using the same settings as previously described in scheduled 
SRM mode in which 15 data points were acquired over a 30 sec chromatographic peak within a 4 min window. 
Collision energy was optimised for each peptide (Supplementary Table 1).
Samples were prepared so that 1 μ g cell lysate with either 1 fmol or 0.1 fmol DOSCAT were analysed by SRM 
methodology. Samples were prepared by serial dilution of the master mix sample with the cell lysate only digest. 
Both isotopic variants of each target peptide were analysed by three transitions. The final transition list was 
divided in two runs to achieve a minimum dwell time of 30 msec with each sample being analysed with both 
transition lists.
Data were analysed by Skyline32 and absolute quantification values were calculated from the standard:analyte 
ratio and the known concentration of internal stable isotope labelled standard. Quantification as copies per cell 
was derived from knowledge of the number of cells loaded onto the column and the loading of the accurately 
quantified DOSCAT standard. For the Iκ Bα peptide GSEPWK, neither analyte nor DOSCAT standard could be 
measured. This could be due to a lack of peptide fragmentation or poor chromatographic behaviour16. Despite 
having peptides chosen based on experimental evidence, neither Iκ Bβ nor Iκ Bε could be quantified by SRM-MS 
due to a combination of miscleavage potential in the standard, poorly performing peptides and the intrinsic low 
abundance of the target proteins. All raw data files were deposited in PASSEL with accession number PASS00979.
Quantitative western blotting and data analysis. A volume of master mix was serially diluted 
in SK-N-AS cell lysate (of equal SK-N-AS cell lysate concentration to that of the master mix) containing no 
DOSCAT so as to create a series of samples which contained a range of DOSCAT concentrations. A six-point 
DOSCAT calibration curve and six technical replicates of the SK-N-AS cell lysate were analysed by automated 
western blotting (Wes, ProteinSimple, CA) for each protein.
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Samples were prepared for Simple Western analysis according to the ProteinSimple user manual. 
Samples were mixed at a 4:1 ratio with a 5× master mix (ProteinSimple) containing SDS, 40 mM DTT and 
fluorescent molecular weight standards and heated at 95°C for 5 min. Samples plus biotinylated molec-
ular weight standards (ProteinSimple) were loaded along with blocking solution, wash buffers, primary anti-
bodies, horseradish-peroxidase conjugated secondary antibodies and chemiluminescent substrate into a 
plate prefilled with stacking and separation matrices. Antibodies were used at concentrations as detailed in 
Supplementary Table 2. Fully automated western blotting was performed using the Wes system; proteins were 
separated by electrophoreses at 375 V for 25 min, immobilised to the capillary by proprietary UV crosslinking and 
incubated with primary and secondary antibodies for 30 min each. Chemiluminescent signal was captured by a 
charge-coupled device camera and the resulting image was analysed by Compass software (ProteinSimple). All 
Compass data files are included in Supplementary Data. The signal intensity was converted to moles μ g−1 using 
the DOSCAT calibration curve, and subsequently converted to copies per cell.
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